U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H32N2O3
Molecular Weight 456.576
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIPENDOXIFENE

SMILES

CC1=C(N(CC2=CC=C(OCCN3CCCCC3)C=C2)C4=C1C=C(O)C=C4)C5=CC=C(O)C=C5

InChI

InChIKey=JICOGKJOQXTAIP-UHFFFAOYSA-N
InChI=1S/C29H32N2O3/c1-21-27-19-25(33)11-14-28(27)31(29(21)23-7-9-24(32)10-8-23)20-22-5-12-26(13-6-22)34-18-17-30-15-3-2-4-16-30/h5-14,19,32-33H,2-4,15-18,20H2,1H3

HIDE SMILES / InChI

Molecular Formula C29H32N2O3
Molecular Weight 456.576
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pipendoxifene (ERA-923) is a selective estrogen receptor modulator with a distinct profile compared with tamoxifen. In particular, unlike tamoxifen, ERA-923 is devoid of uterotropic activity and does not stimulate the growth of endometrial tumors in the EnCa-101 (human endometrial adenocarcinoma that is continuously passaged in animals in the presence of estrogen) experimental mice model. These data may indicate that, in patients, ERA-923 will not increase the incidence of endometrial hyperplasia or cancer. ERA-923 inhibits estrogen-stimulated ER-alpha-dependent tumor growth with equal effects compared with tamoxifen in models sensitive to tamoxifen. ERA-923 partially or completely overcomes tamoxifen resistance. In vivo combination of temsirolimus and ERA-923 at certain doses and schedules completely inhibited breast carcinoma growth, while individual agents were only partially effective. Pipendoxifene had been in phase II clinical trial for the treatment of refractory metastatic breast cancer. However, this research has been discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Current status of selective estrogen receptor modulators (SERMs).
2003 Jan-Feb
Selective estrogen receptor modulators: an update on recent clinical findings.
2008 Mar
Patents

Patents

Sample Use Guides

Once-daily 10-200 mg for 28 days
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:26:02 UTC 2023
Edited
by admin
on Fri Dec 15 15:26:02 UTC 2023
Record UNII
TPC5Q8496G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIPENDOXIFENE
INN   WHO-DD  
INN  
Official Name English
2-(P-HYDROXYPHENYL)-3-METHYL-1-(P-(2-PIPERIDINOETHOXY)BENZYL)INDOL-5-OL
Common Name English
pipendoxifene [INN]
Common Name English
Pipendoxifene [WHO-DD]
Common Name English
ERA-923
Code English
Classification Tree Code System Code
NCI_THESAURUS C1821
Created by admin on Fri Dec 15 15:26:02 UTC 2023 , Edited by admin on Fri Dec 15 15:26:02 UTC 2023
Code System Code Type Description
FDA UNII
TPC5Q8496G
Created by admin on Fri Dec 15 15:26:02 UTC 2023 , Edited by admin on Fri Dec 15 15:26:02 UTC 2023
PRIMARY
SMS_ID
300000034282
Created by admin on Fri Dec 15 15:26:02 UTC 2023 , Edited by admin on Fri Dec 15 15:26:02 UTC 2023
PRIMARY
PUBCHEM
6433099
Created by admin on Fri Dec 15 15:26:02 UTC 2023 , Edited by admin on Fri Dec 15 15:26:02 UTC 2023
PRIMARY
WIKIPEDIA
Pipendoxifene
Created by admin on Fri Dec 15 15:26:02 UTC 2023 , Edited by admin on Fri Dec 15 15:26:02 UTC 2023
PRIMARY
NCI_THESAURUS
C1874
Created by admin on Fri Dec 15 15:26:02 UTC 2023 , Edited by admin on Fri Dec 15 15:26:02 UTC 2023
PRIMARY
EPA CompTox
DTXSID40870209
Created by admin on Fri Dec 15 15:26:02 UTC 2023 , Edited by admin on Fri Dec 15 15:26:02 UTC 2023
PRIMARY
DRUG BANK
DB05414
Created by admin on Fri Dec 15 15:26:02 UTC 2023 , Edited by admin on Fri Dec 15 15:26:02 UTC 2023
PRIMARY
CAS
198480-55-6
Created by admin on Fri Dec 15 15:26:02 UTC 2023 , Edited by admin on Fri Dec 15 15:26:02 UTC 2023
PRIMARY
INN
8077
Created by admin on Fri Dec 15 15:26:02 UTC 2023 , Edited by admin on Fri Dec 15 15:26:02 UTC 2023
PRIMARY
ChEMBL
CHEMBL44426
Created by admin on Fri Dec 15 15:26:02 UTC 2023 , Edited by admin on Fri Dec 15 15:26:02 UTC 2023
PRIMARY
Related Record Type Details
TARGET->DEGRADER, SELECTIVE
87% efficacy relative to Fulvestrant
EC50
CELL->INHIBITOR
Viability
IC50
TARGET -> INHIBITOR
Transcription inhibition
IC50
Related Record Type Details
ACTIVE MOIETY